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Abstract
Background: Copy-number variations (CNVs) are structural variations in the genome involving
1 kb to 3 mb of DNA. CNV has been reported within intron 1 of the BMPR2 gene. We propose
that CNV could affect phenotype in familial and/or sporadic pulmonary arterial hypertension (PAH)
by altering gene expression.
Methods: 97 human DNA samples were obtained which included 24 patients with familial PAH,
18 obligate carriers (BMPR2 mutation positive), 20 sporadic PAH patients, and 35 controls. Two
sets of primers were designed within the CNV, and two sets of control primers were designed
outside the CNV. Quantitative PCR was performed to quantify genomic copies of CNV and control
sequences.
Results: A CNV in BMPR2 was present in one African American negative control subject.
Conclusion: We conclude that the CNV in intron 1 in BMPR2 is unlikely to play a role in the
pathogenesis of either familial or sporadic PAH.
Trial Registration: NIH NCT00091546.
Background
Pulmonary arterial hypertension is a progressive disease
characterized by obstruction of pre-capillary pulmonary
arteries. Symptoms of PAH include fatigue and shortness
of breath. Sustained pulmonary arterial hypertension
eventually leads to right-sided heart failure and death. In
2000, mutations in BMPR2 (bone morphogenic protein
receptor type 2) located on chromosome 2 were shown to
cause familial PAH[1]. The BMPR2 gene spans 190 kb but
encodes only a 4 kb transcript. It contains 13 exons and a
large first intron composed of over 90 kb with frequent
repetitive sequences. BMPR2  mutations are present in
over 80% of patients diagnosed with familial PAH and are
responsible for some cases of idiopathic PAH. Although
the discovery of the BMPR2 mutation has enhanced our
understanding of PAH, there are several important charac-
teristics of the disease which remain unexplained. For
example, the lifetime risk of developing PAH with the
BMPR2  mutation is less than 20%, anticipation is
observed, and there are both familial and sporadic
patients without the BMPR2  mutation who develop
PAH[2]. Recently, penetrance has been linked to levels of
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BMPR2; unaffected carriers (patients with a BMPR2 muta-
tion who do not have PAH) have higher levels of wild-
type BMPR2 allele transcript than patients with BMPR2
mutations and PAH[3]. This finding suggests that altera-
tions of gene expression may be relevant to PAH pheno-
type.
CNVs contribute to genetic variation through insertion,
deletion, or inversion of DNA. Examples of diseases in
which CNV participates mechanistically include DiGeorge
syndrome, Angelman syndrome, Alzheimer's, autism, and
schizophrenia[4]. Cystic fibrosis is an example of a pul-
monary disease where CNV modulates gene expression.
In transgenic mice, deletion of DNase I hypersensitive site
in intron 1 did not change CFTR (cystic fibrosis trans-
membrane conductance regulator) expression in the lung,
but it decreased expression of CFTR in the intestine by
about 60%. Therefore, CNV in intron 1 in the CFTR gene
acts as a regulatory element and is required for normal
CFTR expression in the intestinal epithelium[5].
Recent advancements in array technology have allowed
investigators to perform genome-wide assessments of
genetic variation. To date, there are well over twenty thou-
sand CNVs listed in the Database of Genomic Variants.
The Database of Genomic Variants lists seven partially
overlapping CNVs within intron 1 of BMPR2 on chromo-
some 2 consisting of a deletion of a several kilobase
region[6]. Since intron 1 can contain regulatory elements,
as demonstrated in cystic fibrosis, CNV in intron 1 of
BMPR2 may be an important modifier in PAH. We pro-
pose that CNV in intron 1 of BMPR2 could affect pene-
trance, anticipation, or disease phenotype in familial and/
or sporadic PAH.
Methods
The Database of Genomic Variants was queried for CNV
within the BMPR2 gene. The database identified seven
CNVs in intron 1 at locus 2q33.1: 202,992,448 –
203,030,002. The CNVs were partially overlapping, but
had different endpoints (Figure 1). They were discovered
using a variety of methodologies [6-12]. All seven CNV
studies used samples from the International HapMap
Project which includes individuals of European, Yoruba,
Chinese, and Japanese ancestry.
We designed two sets of primers within the overlapping
CNV region: CNV set 1 (GCATTGAAAGTGGGATAATGG,
TGAAATTTGAGGATAACAATTTTAAG) and CNV set 2
(TAATTGCCTTCAGAGCAGGG, CCAACATTTGTCAAG-
GATGC). We designed two sets of control primers outside
the CNV (one control primer set was placed within exon
1 of BMPR2 and the other control primer set was placed
within exon 1 of BMPR1a): CNV set 1 (TTGTGATTCGCT-
CACAGGAG, AGAGGCTGCCCCTTCTAGTC) and CNV
set 2 (TGGTAAAGGCCGATATGGAG, ATGTTTTCAT-
GGCGCATTAG) (Figure 1).
Human genomic DNA was obtained with informed con-
sent from 97 patients with approval from the Institutional
Review Board at Vanderbilt University. Genomic DNA
was isolated from whole blood using the Roche MagNA
Pure LC DNA purification system (Roche Molecular Bio-
chemicals, Indianapolis, IN). Of the 97 samples, there
were 24 patients with familial PAH, 18 obligate carriers
(BMPR2 mutation positive), 20 sporadic PAH patients,
and 35 controls. Obligate carriers are patients without
pulmonary hypertension, but with BMPR2  mutations.
Controls were either married-in spouses (7), unaffected
family members negative for the BMPR2 mutation (13),
or unrelated healthy individuals (14). There were 21 fam-
ilies with familial PAH included, representing on average
113 BMPR2 alleles. In efforts to evaluate penetrance and
anticipation, we included seven parent-child dyads. 93
patients were Caucasian and 4 patients were African
American.
CNV and primer set location in the BMPR2 genome Figure 1
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DNA samples were diluted to 2 ng/ml. Quantitative PCR
with SYBR Green was performed to quantify genomic cop-
ies of CNV and controls. Samples were run in triplicates
on an Applied Biosystems StepOnePlus machine. A dilu-
tion series was performed to quantify primer efficiency.
Results and Disscusion
CNV in BMPR2 was present in one out of 97 samples. The
CNV was in an African American control and consisted of
a loss of one copy of the CNV region. Figure 2 represents
the ratio of CNV to genomic DNA in the control, obligate,
familial, and sporadic patients. Small variation from a
ratio of 1.0 is caused by noise inherent to the quantitative
PCR process. Since the reported CNV from the HapMap
Project contained individuals of European, Yoruba, Chi-
nese, and Japanese ancestry, it is likely that the CNV in
BMPR2 in our patient is attributable to an ethnic basis.
Conclusion
The recent discovery of differences in levels of BMPR2
allele transcript among affected PAH patients and unaf-
fected carriers led us to look for a CNV within the BMPR2
gene which could affect gene expression. We succeeded in
identifying CNV in BMPR2 in intron 1 in one patient;
however, the patient was a control subject. It is unlikely
that CNV within BMPR2 intron 1 plays a role in the patho-
genesis of either familial or sporadic PAH.
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